

Jamie Palmeroni-Lavis | Counselor

McDougall Communications | 121 Rue de Ville | Rochester, NY 14618

Direct: +1.585.434.2151 | Mobile: +1.585.478.4338

jamie@mcdougallpr.com | [@mcdougallPR](https://twitter.com/mcdougallPR)

Sign up for our [Snapshots](#) newsletter, for insights straight to your inbox

CooperVision, CORE Share Insights from Myopia Clinical Trial at the Global Council on Myopia Management's 2019 Conference

TORONTO, June 3, 2019—Eye care professionals and researchers from Canada and around the world will gather at the Global Council on Myopia Management's 2019 Conference June 7 and 8, 2019. CooperVision, Inc. – a platinum sponsor of the event – as well as Paragon Vision Sciences, a member of CooperVision's Specialty Eye Care Division, will be on site championing the best way to manage myopia progression and improve treatment of the condition.

Dr. Jill Woods, Research Manager and Senior Clinical Scientist at the Centre for Ocular Research and Education (CORE), will be sharing four-year results from CooperVision's landmark MiSight® 1 day myopia management clinical trial during her breakout session on Saturday, June 8 at 1:00 p.m.

"Myopia is affecting children at a much younger age, causing them to have a much higher prescription in their teen and adult years. This can lead to serious eye conditions down the road," said Woods. "The MiSight® 1 day clinical trial illustrates the benefits of beginning myopia management early and shows how a contact lens management solution can maximize the benefit to the child."

The clinical trial has shown the significant impact of a contact lens management approach to slowing the progression of myopia in children. After year three, myopia progression slowed in children wearing the MiSight® 1 day contact lens: 59% as measured by mean cycloplegic spherical equivalent (SE) and 52% as measured by mean axial elongation of the eye when compared to the children in the control group wearing a single vision 1-day contact lens.¹

Blanchard Contact Lenses, another member of CooperVision's Specialty Eye Care Division, will also be at GCOMM promoting its scleral contact lenses designed to treat a variety of eye conditions.

###

1. Chamberlain P, Back, A. Lazon, P, et al. 3 year effectiveness of a dual focus 1 day soft contact lens for myopia control. Presented at BCLA 10 June 2017, Liverpool, United Kingdom

About CooperVision

CooperVision, a unit of The Cooper Companies, Inc. (NYSE:COO), is one of the world's leading manufacturers of soft contact lenses. The Company produces a full array of monthly, two-week and daily disposable contact lenses, all featuring advanced materials and optics. CooperVision has a strong heritage of solving the toughest vision challenges such as astigmatism and presbyopia; and offers the most complete collection of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit coopervision.com.

About The Cooper Companies

The Cooper Companies, Inc. ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in Pleasanton, Calif., Cooper has more than 12,000 employees with products sold in over 100 countries. For more information, please visit www.coopercos.com.